Teleflex Incorporated (NYSE:TFX) issued an update on its FY17 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $8.30-8.40 for the period, compared to the Thomson Reuters consensus estimate of $8.29.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.12. The company had revenue of $534.70 million during the quarter, compared to the consensus estimate of $522.94 million. Teleflex had a return on equity of 16.12% and a net margin of 12.36%. The firm’s revenue was up 17.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.80 EPS.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Wednesday, November 15th will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 0.57%. Teleflex’s dividend payout ratio is presently 26.00%.

A number of research firms recently commented on TFX. Leerink Swann raised Teleflex from a market perform rating to an outperform rating and boosted their price target for the stock from $227.00 to $266.00 in a report on Thursday, September 7th. Zacks Investment Research cut Teleflex from a buy rating to a hold rating in a report on Thursday, August 31st. Jefferies Group LLC reissued a buy rating and issued a $230.00 price target on shares of Teleflex in a report on Thursday, August 3rd. KeyCorp reissued a hold rating on shares of Teleflex in a report on Wednesday, September 6th. Finally, BidaskClub cut Teleflex from a buy rating to a hold rating in a report on Monday, July 31st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $260.75.

In other news, Director Stephen K. M.D. Klasko sold 200 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $241.88, for a total transaction of $48,376.00. Following the sale, the director now directly owns 8,080 shares of the company’s stock, valued at approximately $1,954,390.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.39% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This article was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with's FREE daily email newsletter.